Core Viewpoint - The article discusses the transfer of shares of Innovent Biologics (09939) from Futu Securities International Hong Kong to BOC International Securities, with a total market value of HKD 124 million, representing 11.04% of the shares [1] Group 1: Share Transfer and Agreement - On July 31, shareholders of Innovent Biologics transferred shares valued at HKD 124 million to BOC International Securities, accounting for 11.04% of the total shares [1] - Innovent Biologics announced an agreement with Dr. Tong Youzhi and the seller (KT International Investment Limited) to sell 20.673 million shares at a price of HKD 2.08 per share, which is approximately 4.62% of the company's issued share capital [1] Group 2: Fundraising Purpose - The placement and subscription are aimed at supplementing the long-term funding for the group's general business and growth strategy [1] - The net proceeds from the subscription are estimated to be approximately HKD 40.34 million after deducting related expenses, which will be used for general working capital and business operations [1]

Group 1 - WuXi AppTec (02359) announced a placement agreement with placement agents to issue 73.8 million new H-shares at a price of HKD 104.27 per share, representing approximately 16.01% of the enlarged issued H-shares and 2.51% of the total issued shares post-placement [2] - The placement price reflects a discount of about 6.90% compared to the last trading price of HKD 112.00 per share on July 30, 2025 [2] - The net proceeds from the placement are expected to be approximately HKD 7.65 billion, with about 90% allocated for accelerating global expansion and capacity building, and about 10% for general corporate purposes [2]

配售的募集资金净额(经扣除相关成本及费用、佣金及交易征费)预计约为76.5亿港元(按每股配售股份净 价约103.62港元计算)，将按以下方式投入使用：约90%将用于加速推进全球布局和产能建设;及约10% 将用于一般公司用途。 药明康德（603259）(02359)发布公告，董事会欣然宣布于2025年7月31日，公司与配售代理订立配售协 议，据此，公司同意委任配售代理而配售代理各自同意(而非共同，亦非共同及个别)出任公司代理，并 尽力促使承配人按照配售协议所载条款及条件，按每股配售股份配售价合共认购7380万股新H股。 配售股份数目占紧随完成后经发行配售股份扩大后的已发行H股总数及已发行股份总数约16.01%及 2.51%(假设于本公告日期至完成期间所有配售股份均获认购，且除公司发行配售股份外，已发行股份总 数不会变动)。配售价每股配售股份104.27港元较：2025年7月30日(即紧接配售协议日期前最后一个交易 日)香港联交所所报收市价每股H股112.00港元折让约6.90%。 ...

药明康德：拟折价6.9%配售7380万股H股 筹资77亿港元 金十数据7月31日讯，药明康德(02359.HK)在港交所公告，于2025年7月31日（交易时间前），本公司与 配售代理订立配售协议，据此，本公司同意委任配售代理而配售代理各自同意出任本公司代理，并尽力 促使承配人按照配售协议所载条款及条件，按每股配售股份配售价合共认购7380万股新H股。配售价为 104.27港 元，较最新收盘价折价6.9%。假设所有配售股份获悉数认购，配售的募集资金总额预计将约 为77亿港元。配售的募集资金将为公司提供可用资金，加速推进全球布局和产能建设， 驱动本公司长 期发展等。 ...

Core Viewpoint - E-Surfing Technology (02550) has transferred shares worth HKD 113 million from BNP Paribas to the Hong Kong Stock Connect, representing 5.21% of the total shares [1] Group 1: Share Transfer and Market Impact - On July 29, E-Surfing Technology's shareholder transferred shares valued at HKD 113 million to the Hong Kong Stock Connect [1] - The transfer accounts for 5.21% of the company's total shares [1] Group 2: Share Placement and Subscription Agreement - On July 24, 2025, E-Surfing Technology entered into a placement and subscription agreement with its controlling shareholder, Growth Value LTD, and the placement agent [1] - The seller intends to sell 65.787 million shares at a placement price of HKD 5.26, which is approximately 14.7% lower than the last trading price of HKD 6.17 [1] - The company plans to issue 65.787 million subscription shares to the seller at the same price of HKD 5.26 per share [1]

Core Viewpoint - The company Meizhong Jiahua (02453) has entered into a placement agreement with Guotai Junan International, aiming to issue approximately 48.72 million shares at a price of HKD 5.54 per share, representing about 18.38% of the existing H shares and 6.63% of the total issued shares as of the announcement date [1] Group 1 - As of July 29, shareholders of Meizhong Jiahua deposited shares worth HKD 311 million into BNP Paribas, accounting for 18.38% of the company's market value [1] - The placement will involve a total of 48.72 million shares, which will increase the total issued H shares by approximately 15.52% and the total issued shares by about 6.22% after the placement [1] - The company will apply to the Hong Kong Stock Exchange for the approval of the listing and trading of the placement shares [1]

Core Viewpoint - The company has entered into a placement agreement to issue new H shares at a price of HKD 82, raising capital through the placement of 30,155,450 shares, which represents approximately 6.83% of the company's existing share capital as of the announcement date [1] Group 1 - The placement shares will be allocated to no fewer than six independent third-party subscribers, ensuring that they are not connected to the company or its related parties [1] - The issued shares will be based on the general authorization for issuance and distribution [1] - After the placement, the total issued share capital will increase to approximately 6.39% assuming no other changes in the issued share capital from the announcement date until the completion of the placement [1]

港股微创机器人跌超10%。根据公告，该公司宣布计划向若干投资者配售其新H股。根据建议配售事 项，预期公司将根据于2024年6月25日举行的公司股东周年大会上授予公司董事的一般授权，透过若干 配售代理向投资者配售其新H股。 ...